ImmunoCellular Therapeutics Fully Funded to End of Phase II Trials

ImmunoCellular Therapeutics fully funded to end of Phase II trials – Dr John Yu, Interim CEO and President of ImmunoCellular Therapeutics (NYSE:IMUC) tells Proactiveinvestors that its fully funded through to the end of the Phase IIb at the end of 2013. Dr Yu says that at this time it’s anticipated that it will be able to demonstrate the success the company’s approach to this type of cancer therapy.

Recent Catalysts For Peregrine Pharmaceuticals

Filed under: drug treatment news 2013

On Wednesday, the Food and Drug Administration advanced Cotara as a treatment for glioblastoma, the most common and aggressive type of brain cancer, into the pivotal phase III trial. The company wants to compare two dose levels of the drug in up to 300 …
Read more on Seeking Alpha

Big Movers: Hi-Tech Pharmacal Co.(NASDAQ:HITK), Apple Inc.(NASDAQ:AAPL)

Filed under: drug treatment news 2013

The reason behind the growth in revenue of ECR was increased sales of the pain and fever drug Bupap, as customers bought the same in larger quantities fearing price rise, cough treatment TussiCaps, headache treatment Orbivan and dermatitis drug DexPak …
Read more on Mesh Press (press release)